Pre-Open Stock Movers 04/14: (GALT) (MBRX) (IDEX) Higher; (BBBY) (MFH) (DISCK) Lower (more...)
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Today's Pre-Open Stock Movers:
Galectin Therapeutics Inc. (NASDAQ: GALT) 33% HIGHER; announced that a paper published in the peer-reviewed Journal for ImmunoTherapy of Cancer (JITC), the highest ranked fully open access immunology journal, provides further clinical evidence that using belapectin, a potent galectin-3 inhibitor, in combination with pembrolizumab (KEYTRUDA®), a PD-1 inhibitor, significantly enhances tumor response to immunotherapy in patients with advanced metastatic melanoma (MM) and head and neck squamous cell carcinoma (HNSCC).
Bed Bath & Beyond (NASDAQ: BBBY) 11.2% LOWER; reported Q4 EPS of $0.40, $0.09 better than the analyst estimate of $0.31. Revenue for the quarter came in at $2.62 billion versus the consensus estimate of $2.63 billion.
Moleculin Biotech, Inc., (Nasdaq: MBRX) 9.9% HIGHER; announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPD) to its p-STAT3 inhibitor, WP1066, for the treatment of ependymoma.
Mercurity Fintech Holding Inc. (Nasdaq: MFH) 9% LOWER; announced that three investors, namely Kaiyu Chen, Baibang Technology Co., Ltd. and Le Chai Wow Group Holding Ltd, have agreed to purchase a total of 537,143,470 ordinary shares of the Company and warrants to purchase up to 537,143,470 Ordinary Shares for an aggregate consideration of US$10,000,000, to be settled in the form of 172.9354 bitcoins.
Ideanomics Inc. (NASDAQ: IDEX) 6% HIGHER; Roth Capital initiates coverage with a Buy rating and a price target of $7.00.
The Lovesac Company (NASDAQ: LOVE) 5% HIGHER; reported Q4 EPS of $1.37, $0.79 better than the analyst estimate of $0.58. Revenue for the quarter came in at $129.7 million versus the consensus estimate of $116.13 million.
Discovery, Inc. (NASDAQ: DISCK) 5% LOWER; Large Credit Suisse blocks for sale.
SAP SE (NYSE: SAP) 4% HIGHER; Raises Full-Year Outlook
Stitch Fix, Inc. (NASDAQ: SFIX) 4% LOWER; announced Founder and CEO Katrina Lake will transition to the role of Executive Chairperson of the Board, effective August 1, 2021. Stitch Fix's Board of Directors will be appointing President, Elizabeth Spaulding, to the role of Chief Executive Officer of Stitch Fix and electing her to the Board of Directors, effective August 1 2021.
Discovery, Inc. (NASDAQ: DISCA) 3.5% LOWER; Large Credit Suisse blocks for sale.
Amicus Therapeutics (NASDAQ: FOLD) 3.5% HIGHER; Cantor Fitzgerald upgraded from Neutral to Overweight with a price target of $17.00.
iQIYI (NASDAQ: IQ) 3% LOWER; Large Credit Suisse blocks for sale.
Atlassian Corporation Plc (NASDAQ: TEAM) 2.8% HIGHER; Total revenue in the approximate range of $566 million to $572 million for the third quarter of fiscal year 2021.
Zosano Pharma (NASDAQ: ZSAN) 2.8% HIGHER; received U.S. Food and Drug Administration comments and recommendations to the Company’s proposed pharmacokinetic (PK) study protocol for Qtrypta™. Based on these comments, the Company plans to make the recommended changes to the study protocol and proceed with finalizing the protocol, study site selection and study conduct.
Moderna, Inc. (Nasdaq: MRNA) 0.5% HIGHER; announced clinical and supply updates on its COVID-19 Vaccine program. New results from a preclinical study of the Companys COVID-19 variant-specific vaccine candidates showed that the Companys variant-specific booster vaccine candidates (mRNA-1273.351 and mRNA-1273.211) increase neutralizing titers against SARS-CoV-2 variants of concern. To date, the Company has delivered approximately 132 million doses of the Moderna COVID-19 Vaccine globally.
Snap Inc (NYSE: SNAP) 1% HIGHER; Wedbush assumes, upgraded from Neutral to Outperform with a price target of $75.00 (from $52.00).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pre-Open Stock Movers 05/13: (AMRK) (SI) (SONO) Higher; (WISH) (POSH) (TDUP) Lower (more...)
- Roblox (RBLX) Gains as Sales Rise 140%, Analyst Raises PT on Strong Growth and Early China Launch
- Emergent BioSolutions (EBS) issued a statement on the status of its response to FDA
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesCredit Suisse, Cantor Fitzgerald, Roth Capital, Pre-Open Losers, Pre-Open Winners, Pre Market Movers, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!